Amendments to the Claims:

Please amend the claims to read as follows:

1. - 3. (Cancelled)

4. (Re-presented and amended) The ~~pharmacological~~pharmaceutical agent of claim ~~2~~11 wherein the therapeutically effective amount the extract of *Uncaria tomentosa* is obtained from a commercially available source.

5. (Re-presented and amended) The ~~pharmacological~~pharmaceutical agent of claim 4 wherein the commercially available source of Uncaria tomentosa is selected from the group consisting of pills, tablets, caplets, soft and hard gelatin capsules, lozenges, sachets, cachets, vegicaps, liquid drops, elixers, suspensions, emulsions, solutions, syrups, tea bags, aerosols ~~(as a solid or in a liquid medium)~~, suppositories, sterile injectable solutions, sterile packaged powders, bark bundles ~~or~~and bark powder.

6. (Cancelled)

7. (Re-presented and amended) The ~~pharmacological~~pharmaceutical agent of claim ~~2~~11 wherein the therapeutically effective amount of *Uncaria tomentosa* comprises a dosage in the range of from about 10 to 1,000 mg/kg of body weight of the patient.

8. (Re-presented and amended) The ~~pharmacological~~pharmaceutical agent of claim 7 wherein the therapeutically effective amount of *Uncaria tomentosa* comprises a dosage in the range of from about 10 to 100 mg/kg of body weight of the patient.

9. (Cancelled)

10. (Re-presented and amended) The ~~pharmacological~~pharmaceutical agent of claim ~~9~~11 wherein ~~said~~the amyloid disease ~~for treatment~~ is Alzheimer's Disease.

11. (Currently Amended) ~~The~~A pharmaceutical agent ~~of claim 3~~for treating an amyloid disease in a patient, wherein the agent comprises a therapeutically effective amount of an extract obtained from the inner bark or root tissue of a plant of the genus *Uncaria*, species *tomentosa*, wherein the weight percentage of plant extract in the agent is in the range of from about 70% to about 95%.

12. (Re-presented and amended) The pharmaceutical agent of claim 11 further comprising a pharmaceutically acceptable carrier, diluent or excipient.

13. (Re-presented and amended) The pharmaceutical agent of claim ~~2~~11 wherein the therapeutically effective amount of ~~plant matter~~the extract has an amyloid inhibitory activity or efficacy greater than 50%.

14.-47. (Cancelled)

48. (Re-presented and amended) The ~~pharmacological~~pharmaceutical agent of claim ~~46~~52 wherein the therapeutically effective amount of *Uncaria tomentosa* comprises a dosage in the range of from about 10 to 1,000 mg/kg of body weight of the patient.

49. (Re-presented and amended) The ~~pharmacological~~pharmaceutical agent of claim 48 wherein the therapeutically effective amount of *Uncaria tomentosa* comprises a dosage in the range of from about 10 to 100 mg/kg of body weight of the patient.

50. (Cancelled)

51. (Re-presented and amended) The ~~pharmacological~~pharmaceutical agent of claim ~~50~~52 wherein ~~said~~the amyloid disease ~~for treatment~~ is Alzheimer's Disease.

52. (Currently Amended) ~~The~~A pharmaceutical agent ~~of claim 46~~comprising a therapeutically effective amount of an extract obtained from the inner bark or root tissue of a plant of the genus *Uncaria*, species *tomentosa*, the therapeutic amount of the extract selected for efficacy in treating an amyloid disease in a patient, wherein the weight percentage of plant extract in the agent is in the range of from about 70% to about 95%.

53. (Re-presented and amended) The pharmaceutical agent of claim ~~46~~52 further comprising a pharmaceutically acceptable carrier, diluent or excipient.

54. (Re-presented and amended) The pharmaceutical agent of claim ~~46~~52 wherein the therapeutically effective amount of ~~plant matter~~extract has an amyloid inhibitory activity or efficacy greater than 50%.

Respectfully submitted,

P07-revAmd.RSP

PATRICK MICHAEL DWYER
Reg. No. 32,411

PROTEOTECH, INC.
1818 WESTLAKE AVENUE N, SUITE 114
SEATTLE, WA 98109